Campath and Breastfeeding
No research has been done to see if Campath (alemtuzumab) would pass through human breast milk. However, the drug does weaken the immune system, potentially leaving a woman vulnerable to infections, and this could pose a risk to a nursing child. According to the manufacturer's recommendations, breastfeeding women should not use Campath.
Campath® (alemtuzumab) is a prescription medication that belongs to a group of drugs called monoclonal antibodies. It is approved to treat people with leukemia. At this time, it is not known whether Campath passes through breast milk. The manufacturer recommends women not breastfeed while using it.
Campath has not been studied in breastfeeding women. Therefore, it is unknown whether the medicine passes through breast milk or whether it would harm a nursing child.
Campath is a synthetic, or manufactured, form of immunoglobulin G (IgG) antibody, a protein made by the immune system. Natural IgG antibodies can pass through breast milk, so it is likely that Campath could pass through breast milk as well. However, it is unclear how much medicine would actually reach a nursing child's bloodstream. Normally, very little IgG is absorbed from the digestive tract into the bloodstream, which is why the drug is given as an intravenous injection instead of by mouth.
It is important to keep in mind that Campath may cause potentially dangerous side effects, such as low blood cell counts and increased risk for infection. Because of the potential for these serious side effects in a nursing infant, the manufacturer recommends that women not breastfeed during treatment.
You should discuss breastfeeding and Campath with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.